USeP instructor: weight-loss drug cannot fix spaces that shame plus-size women
In a Mindanao Times column, Kethelle Sajonia argues that tirzepatide offers real health gains but that confidence should not depend on getting smaller.
Kethelle I. Sajonia, a college instructor at the University of Southeastern Philippines (USeP) Mintal Campus in Davao City, argues in a column for Mindanao Times that the popular weight-loss medicine tirzepatide can change women's bodies but not the culture and public spaces that make plus-size Filipino women feel unwelcome.
Writing as a plus-size woman who studies how bodies move through public space, Sajonia acknowledges the drug's results. She cites the SURMOUNT-1 trial published in the New England Journal of Medicine, in which more than 2,500 adults were followed for 72 weeks; those on the highest dose lost about 21% of their body weight on average, compared with about 3% for the placebo group. She also notes that participants reported better quality of life, particularly in physical functioning.
Her concern, she writes, is why confidence so often comes only after a woman becomes smaller. Drawing on what she calls critical body proxemics, she points to narrow chairs in government offices, jeepney seats meant for "ten persons, five on each side," and relatives' comments about weight. When women lose weight, she argues, part of their newfound confidence is relief: "The room didn't learn to welcome her. She changed to fit the room." She cites research by Rebecca Pearl, Rebecca Puhl and colleagues linking internalised weight stigma to poorer health outcomes and avoidance of medical care.
Sajonia also raises cost. The registered pen is expensive and paid out of pocket, she writes, which has fuelled online sellers of cheaper "unbranded" or compounded tirzepatide. She notes that Mounjaro KwikPen is the only tirzepatide product approved by the FDA Philippines, that the agency has warned against unregistered products, and that the Philippine College of Physicians has cautioned that compounded versions have not undergone clinical trials and selling them may violate the Pharmacy Law.
Rather than blaming women who take that route, she calls for affordable legitimate treatment, obesity care through PhilHealth and public clinics, and independent Filipino-led research, noting that SURMOUNT-1 participants were around 70% white and that the SURMOUNT-4 trial found people who stopped the drug regained substantial weight. Citing DOST-FNRI data that obesity among Filipino adults aged 20 to 59 rose to 44.5% in 2025, she argues that women who choose the medicine with their doctors deserve support, while cities, clinics and families should make room for people of every size.
Why it matters for Davao
With DOST-FNRI reporting obesity among 44.5% of working-age Filipino adults, the column raises questions about safe access to weight-loss treatment and how inclusive everyday spaces such as jeepneys and offices are for Davao residents.
This article was written by the DavaoNews desk with AI assistance, using reporting by Mindanao Times. Facts come from the original report, which we credit and link below. Our editorial policy
Discussion (0)
Sign in with Google to join the discussion.
Sign in to commentNo comments yet. Start the conversation.